Ozempic maker Novo Nordisk names rising stock its top risk

Novo Nordisk set a lower share price as a formal goal and the market began the drop.

Debbie Downturn21 Sept 20261 min readShorts

Novo Nordisk set 2030 goals that seek a steady fall in the share price. The stock tumbled after the slides appeared. A later rise is now the risk that would spoil the timetable.

"...falling is the strategy, not the side effect,"

a Novo Nordisk planning officer said on Saturday after the firm set its 2030 goals.

The Ozempic maker wants the share price down nine percent a year until the chart looks finished. It calls the wrecks of 1929 and 2008 a useful guide and left a blank line on the slide for the next one. Shares tumbled once investors saw the deck. People who bet on price drops said the only threat left is a rise that would ruin the schedule and force them to admit they were early.

Its promise is weight loss, and the share price is the heaviest thing it still owns.